In another study of 246 ER+ advanced breast cancers, higher expression of miR-30a-3p, miR-30c and miR-182 was associated with better response to tamoxifen treatment as measured by longer progression-free survival time; however, only miR-30c was shown to be an independent predictor. This evidence concerns the gene ESR1 and breast carcinoma.